<p>BioNexus Gene Lab Corp. 已完成對 Fidelion Diagnostics Pte. Ltd. 的戰略股權投資，通過非現金股權交換獲得 15% 的少數股權。作為回報，Fidelion 現在持有 BioNexus Gene Lab Corp. 發行和流通股票的約 16.6%，使雙方的利益保持一致。根據協議，BioNexus Gene Lab Corp. 還通過許可協議獲得了 VitaGuard™ 腫瘤初始微小殘留病（MRD）液體活檢平台在東南亞的獨家商業權利，許可費用將在 24 個月內分期支付。該交易旨在保持財務實力，最小化稀釋，並支持 BioNexus Gene Lab Corp. 在精準腫瘤學市場的擴展。免責聲明：本新聞簡報由公共技術公司（PUBT）使用生成性人工智能創建。雖然 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。BioNexus Gene Lab Corp. 於 2025 年 12 月 03 日通過 GlobeNewswire（參考 ID：GNW9596053-en）發佈了用於生成本新聞簡報的原始內容，並對其中包含的信息承擔全部責任。© 版權 2025 - 公共技術公司（PUBT）</p>

BGLC

<p>BioNexus Gene Lab Corp.通過非現金股權交換收購了 Fidelion Diagnostics 的 15% 股份，而 Fidelion 持有 BioNexus 16.6% 的股份。BioNexus 獲得了 VitaGuard™ MRD 平台在東南亞的獨家權利，以支持其在精準腫瘤學領域的擴展。該交易旨在保持財務實力並最小化稀釋</p>

<p>BioNexus Gene Lab Corp. has completed a strategic equity investment in Fidelion Diagnostics Pte. Ltd., acquiring a 15% minority stake through a non-cash share swap. In return, Fidelion now holds approximately 16.6% of BioNexus Gene Lab Corp.’s issued and outstanding stock, aligning the interests of both companies. As part of the agreement, BioNexus Gene Lab Corp. also secured exclusive commercial rights to the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform for Southeast Asia via a licensing agreement, with the license fee payable over 24 monthly installments. The deal is designed to preserve financial strength, minimize dilution, and support BioNexus Gene Lab Corp.’s expansion in the precision oncology market. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596053-en) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>
<div class="lb-trans"><p>BioNexus Gene Lab Corp. 已完成對 Fidelion Diagnostics Pte. Ltd. 的戰略股權投資，通過非現金股權交換獲得 15% 的少數股權。作為回報，Fidelion 現在持有 BioNexus Gene Lab Corp. 發行和流通股票的約 16.6%，使雙方的利益保持一致。根據協議，BioNexus Gene Lab Corp. 還通過許可協議獲得了 VitaGuard™ 腫瘤初始微小殘留病（MRD）液體活檢平台在東南亞的獨家商業權利，許可費用將在 24 個月內分期支付。該交易旨在保持財務實力，最小化稀釋，並支持 BioNexus Gene Lab Corp. 在精準腫瘤學市場的擴展。免責聲明：本新聞簡報由公共技術公司（PUBT）使用生成性人工智能創建。雖然 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。BioNexus Gene Lab Corp. 於 2025 年 12 月 03 日通過 GlobeNewswire（參考 ID：GNW9596053-en）發佈了用於生成本新聞簡報的原始內容，並對其中包含的信息承擔全部責任。© 版權 2025 - 公共技術公司（PUBT）</p>
</div>

BioNexus Gene Lab Corp. 收購了 Fidelion Diagnostics 15% 的股份